SCHEMBL27249010

SCHEMBL27249010

CCOc1cccc([N+](=O)[O-])c1C(N)=O

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
LMNA P02545 3/20 0.52
MAPT P10636 2/20 0.49
RECQL P46063 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
MAPK1 P28482 1/20 0.49
NPC1 O15118 3/20 0.47
HTT P42858 1/20 0.47
GAA P10253 1/20 0.46
RAB9A P51151 3/20 0.46
KDM4E B2RXH2 2/20 0.46
L3MBTL1 Q9Y468 4/20 0.45
TDP1 Q9NUW8 2/20 0.45
POLB P06746 2/20 0.44
CTDSP1 Q9GZU7 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27248973 0.87 L3MBTL1 (0.58) ALDH1A1LMNAMAPTRECQLMEN1
SCHEMBL27249061 0.84 ALDH1A1 (0.51) ALDH1A1LMNAMAPTRECQLMEN1
SCHEMBL5202878 0.83 TDP1 (0.64) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL16666142 0.82 GLA (0.52) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL17263053 0.80 ALDH1A1 (0.50) ALDH1A1LMNAMAPTRECQLMEN1
SCHEMBL6807284 0.79 GPR35 (0.61) ALDH1A1LMNAKDM4EL3MBTL1TDP1
SCHEMBL907922 0.78 ALDH1A1 (0.57) ALDH1A1LMNAMAPTRECQLMEN1
SCHEMBL845794 0.78 GPR35 (0.58) ALDH1A1LMNAMAPTRECQLMEN1
SCHEMBL11502863 0.78 MAPT (0.48) ALDH1A1LMNAMAPTRECQLMEN1
SCHEMBL12219497 0.78 KMT2A (0.43) ALDH1A1MAPTKMT2AHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360085-A1 Glucose Uptake Inhibitors KADMON CORPORATION, LLC (US) 2024-10-31 US disclosed
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 US disclosed
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 US disclosed
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 US disclosed
US-20220363648-A1 Glucose Uptake Inhibitors KADMON CORPORATION, LLC 2022-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030857-B2 Glucose uptake inhibitors SLC2A1, SLC2A4, SLC2A2 ALDH1A1 1422/4885LMNA 4856/4885MAPT 1835/4885
US-20220363648-A1 Glucose Uptake Inhibitors SLC2A1, SLC2A4, SLC2A2 ALDH1A1 1422/4885LMNA 4856/4885MAPT 1835/4885
US-20240360085-A1 Glucose Uptake Inhibitors SLC2A3, SLC2A1, SLC2A4 ALDH1A1 1565/4885LMNA 4839/4885MAPT 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.